The anterior saphenous vein. Part 3. Systematic review of the literature and payor coverage policies. Endorsed by the American Vein and Lymphatic Society, the American Venous Forum and the International Union of Phlebology

Phlebology. 2024 Jun;39(5):325-332. doi: 10.1177/02683555231223281. Epub 2024 Mar 25.

Abstract

Objective: The objective of this study is to systemically review the literature on Anterior Saphenous Vein (ASV) reflux treatment and insurance impediments to treatment coverage.

Methods: A literature search was performed using a PRISMA framework. In addition, a cross-sectional analysis of insurance policies for ASV treatment was evaluated.

Results: Published evidence and treatment considerations in the literature for ASV treatment are discussed. In 155 of 226 (68.6%) insurance policies reviewed coverage of ASV ablation was allowed while 62/226 (27.4%) did not specify coverage and 9/226 (4.0%) specified ASV treatment was not covered. Of the 155 that provide ASV coverage, 98 (62.2%) provide coverage with criteria such as requiring prior treatment of the great saphenous vein.

Conclusions: Vein treatment experts should continue to advocate to insurance carriers to update their varicose vein treatment policies to reflect the substantial clinical evidence so that patients with ASV reflux can be appropriately treated.

Keywords: Varicose veins; anatomy; chronic venous insufficiency; recurrenct varices; saphenous vein.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Humans
  • Insurance Coverage / economics
  • Saphenous Vein* / surgery
  • Societies, Medical
  • United States
  • Varicose Veins* / economics
  • Varicose Veins* / therapy
  • Venous Insufficiency / economics
  • Venous Insufficiency / therapy